The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

Some embodiments herein relate generally to compositions comprising microbial organisms and/or metabolites for improving the behavior of a subject, such as a subject having autism spectrum disorder (ASD), and methods of using the same. Some embodiments herein relate generally to profiles of gut bacteria and/or metabolites useful for determining a risk, presence, and/or severity of ASD.

Some embodiments herein relate generally to compositions comprising microbial organisms and/or metabolites for improving the behavior of a subject, such as a subject having autism spectrum disorder (ASD), and methods of using the same. Some embodiments herein relate generally to profiles of gut bacteria and/or metabolites useful for determining a risk, presence, and/or severity of ASD.

Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.

The present invention provides a bile acid or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body, which method comprises administering a therapeutic compound to the human or animal body, wherein: a. said bile acid is chenodeoxycholic acid or deoxycholic acid, and b. optionally, said bile salt is employed in conjunction with EDTA, c. in said method the bile acid or salt thereof, and EDTA, are used to enable or enhance intracellular uptake of the therapeutic compound.

The present invention provides a bile acid or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body, which method comprises administering a therapeutic compound to the human or animal body, wherein: a. said bile acid is chenodeoxycholic acid or deoxycholic acid, and b. optionally, said bile salt is employed in conjunction with EDTA, c. in said method the bile acid or salt thereof, and EDTA, are used to enable or enhance intracellular uptake of the therapeutic compound.

The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.